Loading
YL202 is an experimental antibody-drug conjugate (ADC) from MediLink Therapeutics (Suzhou) in phase 3 trials for non-small-cell lung cancer, HR-positive / HER2-negative breast cancer and colorectal cancer, aimed at HER3.
YL202 is an antibody-drug conjugate (ADC) developed by MediLink Therapeutics (Suzhou). Its target is HER3 (the sponsor names HER3). ClinicalTrials.gov describes the intervention as: YL202 will be intravenously infused over 60±10 min. It is the investigational product in 4 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT07416994 (Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer) and NCT07461454 (YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer), in non-small-cell lung cancer, HR-positive / HER2-negative breast cancer, colorectal cancer and cervical cancer. The largest, NCT07416994, plans to enrol 440 participants with primary completion expected 2028-08-31. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Antibody-drug conjugate (ADC) directed at HER3, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated. Connects to HER3.
1.YL202's antibody arm binds HER3 on the surface of the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"YL202" OR ABSTRACT:"YL202") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about YL202, not a curated reading list.
Shares HER3, HR-positive / HER2-negative breast cancer, Non-small-cell lung cancer and the tag pipeline.
Shares HER3, Cervical cancer, Non-small-cell lung cancer and the tag pipeline.
Shares HER3, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Cervical cancer, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares MediLink Therapeutics and the tag pipeline.
Shares MediLink Therapeutics and the tag pipeline.
Shares MediLink Therapeutics and the tag pipeline.
Shares Cervical cancer, HR-positive / HER2-negative breast cancer, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.